Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Kraman

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2006
CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiationJames M Carr, Marlene J Carrasco, James E D Thaventhiran, et al.
Methods (San Diego, Calif.)|September 13, 2018
Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeuticsKaty L Everett, Matthew Kraman, Francisca P G Wollerton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor ActivityMatthew Kraman, Mustapha Faroudi, Natalie L Allen, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancerChristine Feig, James O Jones, Matthew Kraman, et al.
The Journal of Experimental Medicine|May 29, 2013
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemiaEdward W Roberts, Andrew Deonarine, James O Jones, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2006
CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiationJames M Carr, Marlene J Carrasco, James E D Thaventhiran, et al.
Methods (San Diego, Calif.)|September 13, 2018
Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeuticsKaty L Everett, Matthew Kraman, Francisca P G Wollerton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor ActivityMatthew Kraman, Mustapha Faroudi, Natalie L Allen, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancerChristine Feig, James O Jones, Matthew Kraman, et al.
The Journal of Experimental Medicine|May 29, 2013
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemiaEdward W Roberts, Andrew Deonarine, James O Jones, et al.
Pageof 2